Newsletter | October 11, 2024

10.11.24 -- New Economics Of Cell And Gene Therapy – Part II

SPONSOR

A Full-Service Solution Partner Disrupting the Outsourcing Paradigm

inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them.

FOCUS ON SUPPLY CHAIN

DSCSA Implementation Is Progressing, But More Complexity May Be Coming

The FDA recently announced it would exempt small dispensers from requirements of the Drug Supply Chain Security Act (DSCSA) until Nov. 27, 2026. The industry has made tremendous progress so far with DSCSA, but this discretion will make compliance more challenging.

Monitoring Industry Contamination Down To Single Particle Level

Examine the benefit of using fluoropolymer film bags for the handling and storage of high value oligonucleotides- based payloads.

FOCUS ON CLINICAL TRIALS

New Economics Of Cell And Gene Therapy – Part II

It’s not just about the science. This article explores some steps that can be taken now to make the next generation of CGTs affordable and accessible not just approvable.

Delving Into The Current Global Landscape Of Gastric Cancer Clinical Trials

Gain insights into the evolving landscape of gastric cancer care and examine significant advancements and ongoing challenges in the fight against this formidable disease.

Building An Analytics Culture In Clinical Development

Discover how embracing fast and flexible clinical analytics can help you address clinical questions and provide real-time insights into data issues as they arise.

The High Cost Of CRO Turnover (And How You Can Avoid It)

Though some turnover is an inevitable part of a business’s life cycle, there are several strategies available to ensure a consistent CRO team throughout the span of your trial.

What's Missing From Decentralized Trials? The Human Element

DCTs are complex, often leading to disconnects between sites and providers. A dedicated site management team enhances these relationships, maximizing the value of DCTs.

Automated Study Calendaring For Clinical Trials

Uncover this groundbreaking automated study calendaring system, designed to revolutionize clinical trials by streamlining scheduling, enhancing user engagement, and ensuring timely data collection.

Connect With Cell & Gene: